Novasign

Novasign company information, Employees & Contact Information

Explore related pages

Related company profiles:

Novasign is a young company focused to bring advanced machine learning tools to biotech to ultimately speed up bioprocess development therefore reducing time to market of both new molecules as well as biosimilars. The company is a spin-off from the University of Natural Resources and Life Science Vienna currently based in Vienna in close proximity to the Vienna Institute of Biotechnology

Company Details

Employees
14
Founded
-
Address
Aspernbrückengasse 2, 2 Stock,austria
Phone
43-720778604
Email
co****@****sign.at
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Vienna
Looking for a particular Novasign employee's phone or email?

Novasign Questions

News

Repligen Corporation Reports Q3 2025 Financial Results - TradingView

Repligen Corporation Reports Q3 2025 Financial Results TradingView

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance - The Manila Times

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance The Manila Times

Repligen Partners with Novasign to Further Advance Bioprocessing Digitalization - Genetic Engineering and Biotechnology News

Repligen Partners with Novasign to Further Advance Bioprocessing Digitalization Genetic Engineering and Biotechnology News

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization - GlobeNewswire

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization GlobeNewswire

Repligen partners with Novasign to enhance bioprocessing systems - Investing.com

Repligen partners with Novasign to enhance bioprocessing systems Investing.com

Repligen stock rating reiterated at Buy by H.C. Wainwright - Investing.com

Repligen stock rating reiterated at Buy by H.C. Wainwright Investing.com

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance - The Globe and Mail

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance The Globe and Mail

TD Cowen reiterates Buy rating on Repligen stock, maintains $200 target - Investing.com

TD Cowen reiterates Buy rating on Repligen stock, maintains $200 target Investing.com

Stifel reiterates Buy rating on Repligen stock, maintains $207 price target - Investing.com

Stifel reiterates Buy rating on Repligen stock, maintains $207 price target Investing.com

Repligen director Hunt sells $3.5m in shares By Investing.com - Investing.com Australia

Repligen director Hunt sells $3.5m in shares By Investing.com Investing.com Australia

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant